Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal?
9 years ago
Incyte antes up $200M — promises billions more — to launch a bispecific development deal with Merus
9 years ago
Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal
9 years ago
Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade
9 years ago
Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic
9 years ago
Financing
CRISPR/Cas9 players create an IP alliance as the war with Editas heats up
9 years ago
In a first, AstraZeneca gains rights to an antisense KRAS drug in $165M Ionis deal
9 years ago
Gilead’s rep takes another punishing blow as a bad, no good, awful year just got worse
9 years ago
Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout
9 years ago
After some careful thinking, Celgene strikes a $295M discovery deal on neurodegeneration
9 years ago
FDA slaps a hold on Agios’ PK drug, forcing the biotech to kill it in favor of an internal rival
9 years ago
Pfizer racks up an FDA approval for eczema blockbuster hopeful crisaborole
9 years ago
New drug OKs fell off a cliff in 2016 and the FDA wants you to know why
9 years ago
INC Research promises 550 new jobs as it plots headquarters move
9 years ago
R&D
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
9 years ago
It’s the law: Obama signs widely popular 21st Century Cures Act
9 years ago
GSK preps for vaccine R&D expansion, 200 hires for new global hub
9 years ago
R&D
Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead
9 years ago
R&D
Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca
9 years ago
R&D
The 21st Century Cures Act is here to stay. Now what?
9 years ago
Gilead offers rare apology to payers over the hep C drug sticker shock
9 years ago
Seasteader, drug libertarian and now FDA Commissioner? Peter Thiel backs a radical shift
9 years ago
PEOTUS Donald Trump vows to rein in drug prices, slamming biotech stocks
9 years ago
Is the US biopharma industry headed for a turning point in 2017?
9 years ago
Bioregnum
Opinion
First page
Previous page
336
337
338
339
340
341
342
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit